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Assessment of various continual
reassessment method models for dose-
escalation phase 1 oncology clinical trials:
using real clinical data and simulation
studies
G. D. James1* , S. Symeonides2, J. Marshall3, J. Young4 and G. Clack5
Abstract
Background: The continual reassessment method (CRM) identifies the maximum tolerated dose (MTD) more
efficiently and identifies the true MTD more frequently compared to standard methods such as the 3 + 3 method.
An initial estimate of the dose-toxicity relationship (prior skeleton) is required, and there is limited guidance on how
to select this. Previously, we compared the CRM with six different skeletons to the 3 + 3 method by conducting
post-hoc analysis on a phase 1 oncology study (AZD3514), each CRM model reduced the number of patients
allocated to suboptimal and toxic doses. This manuscript extends this work by assessing the ability of the 3 + 3
method and the CRM with different skeletons in determining the true MTD of various “true” dose-toxicity
relationships.
Methods: One thousand studies were simulated for each “true” dose toxicity relationship considered, four were
based on clinical trial data (AZD3514, AZD1208, AZD1480, AZD4877), and four were theoretical. The 3 + 3 method
and 2-stage extended CRM with six skeletons were applied to identify the MTD, where the true MTD was
considered as the largest dose where the probability of experiencing a dose limiting toxicity (DLT) is ≤33%.
Results: For every true dose-toxicity relationship, the CRM selected the MTD that matched the true MTD in a
higher proportion of studies compared to the 3 + 3 method. The CRM overestimated the MTD in a higher
proportion of simulations compared to the 3 + 3 method.
The proportion of studies where the correct MTD was selected varied considerably between skeletons. For some
true dose-toxicity relationships, some skeletons identified the true MTD in a higher proportion of scenarios
compared to the skeleton that matched the true dose-toxicity relationship.
Conclusion: Through simulation, the CRM generally outperformed the 3 + 3 method for the clinical and theoretical
true dose-toxicity relationships. It was observed that accurate estimates of the true skeleton do not always
outperform a generic skeleton, therefore the application of wide confidence intervals may enable a generic
skeleton to be used. Further work is needed to determine the optimum skeleton.
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Background
The continual reassessment method (CRM) is more effi-
cient for estimating the recommended dose from phase
1 clinical trials for further development than the com-
monly used 3 + 3 method. In addition the 3 + 3 method
leads to more patients than necessary receiving subopti-
mal doses ([1, 2] and it has limitations in its ability to
correctly identify the maximum tolerated dose (MTD).
Studies have found that, compared to the 3 + 3 method,
the CRM allocates fewer patients to suboptimal [3] and
harmful doses ([2, 4] and identifies the true MTD a
higher proportion of the time ([5, 6], reducing the likeli-
hood of making a costly and potentially unsafe decision.
The use of model-based methods including the CRM
in phase 1 trials is low. Literature reviews have found
model-based methods were used in 3.3% of phase 1 trials
between 2007 and 2008 [7], and 1.6% of trials between
1991 and 2006 [8]. A lack of practical guidance for
implementing these methods [9], and increased statis-
tical complexity (e.g. applying a complicated” black box”
algorithm [10]) may be preventing uptake of these
methods. The CRM requires pre-specification of the
dose-toxicity model, which consists of initial estimates
of the probability of experiencing a DLT for each dose
(prior skeleton) and a prior distribution to describe the
underlying confidence in these prior probabilities [9].
The prior distribution is described elsewhere as it has
been investigated previously [11]. Skeleton probabilities
can be estimated using prior knowledge of the dose-
toxicity relationships from pre-clinical or clinical studies
[12]. However, when prior knowledge is unavailable or
there is concern about how reliable the preclinical data
is for estimating the skeleton, the choice of the probabil-
ities in the skeleton is a challenge ([12, 13] and may not
be accurate [7]. We found limited guidance on a stand-
ard skeleton to be used when there is limited knowledge
on dose-toxicity relationship, which is an area of need to
support practical implementation of CRM. An approach
that deserves some consideration is using indifference
intervals to determine prior probabilities [9]. Also,
O’Quigley and Iasonos [14] investigated the relationship
between priors and skeletons.
A common extension of the CRM, is the extended (or
two-stage) CRM [2], which has the advantage of ensur-
ing the first patients are recommended to receive the
lowest dose. The first stage involves enrolling up to
three patients in each cohort, starting with the lowest
dose and escalating one dose each time until the first
DLT is experienced. In the second stage, the CRM
method is updated based on toxicity data and is used to
recommend the next, and all further dose levels to be
tested.
We proposed 6 different skeletons for use in the CRM
when there is limited information about the dose-
toxicity relationship, and post-hoc analysis on AZD3514
showed the CRM with each skeleton identified the true
MTD and reduced the number of patients allocated to
suboptimal and toxic doses compared to the 3 + 3
method [15]. However, the ability of these methods has
only been assessed for one clinical dose-toxicity curve,
therefore it would be useful to assess their performance
in various dose-toxicity relationships to contribute to
guidance on skeletons for the CRM model. The previous
manuscript compared skeletons based on the number of
patients who received optimal and suboptimal doses
using a single sample of the true dose-toxicity curve.
This research assesses the ability of each skeleton to de-
termine the correct MTD for multiple true dose-toxicity
curves. Furthermore, we use simulation so we sample
multiple data from each true dose-toxicity curve gener-
ating a range of trial data which could not be achieved
from a single study which provides a more generally
applicable assessment of performance of the different
approaches in determining the true MTD.
We sought to compare the ability of the Extended-
CRM with Bayesian design, using different skeletons,
with the 3 + 3 method to identify the MTD. “True” clin-
ical dose-toxicity curves were identified from four phase
1 clinical trials: AZD3514, AZD1208, AZD1480 and
AZD4877, and four additional theoretical true dose-
toxicity curves were constructed. Simulations studies
were conducted to identify the proportion of simulations
where the true MTD was identified correctly, underesti-
mated and overestimated using each method. In this
manuscript we present the results of this analysis and
provide recommendations in the discussion to improve
the uptake of these methods. This research has been
presented externally at PSI [16] and PSI [17].
Methods
The highest 5 doses from four phase 1 clinical trials
were used. AZD3514 study 1 (NCT01162395) has been
described before [15]. AZD1208 study 1 (NCT01489722)
consisted of patients with recurrent or refractory Acute
Myelogenous Leukemia (AML) being given AZD1208, a
novel agent that inhibits Proviral Integration Moloney
virus (PIM) kinases 1, 2 and 3. Patients received doses of
AZD1208 monotherapy of 120 mg QD, 240 mg QD, 480
mg QD, 700 mg QD, and 900 mg QD. The highest dose
was considered intolerable, but no MTD was determined
as no dose cohort met the criteria of 6 patients evaluable
for DLT. AZD1480 study 2 (NCT01219543) consisted of
patients with advanced solid malignancies and estimated
glomerular filtration rate or ROS-mutant Non-small cell
lung cancer or non-smokers with lung metastasis. Pa-
tients received doses of 20 mg BID, 30 mg BID, 35 mg
BID and 45mg BID. To extend the range of dose levels
for the dose toxicity relationship for AZD1480, an
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additional dose level, 15 mg AZD1480 BID from
AZD1480 study 4 (NCT01219543), was also included.
AZD4877 study 6 (NCT00471367) consisted of patients
with advanced solid malignancies including lymphoma.
Patients received twice weekly doses of 2 mg, 4 mg, 7
mg, 11 mg and 15mg.
The number and proportion of patients who experi-
enced a DLT, by dose within each study is presented in
Table 1. For each dose we considered the observed pro-
portion of patients who experienced a DLT as the true
dose-toxicity, unless this proportion is lower than the
dose below, in which case the proportion will be the
same as this dose. This formed 4 unique clinical dose-
toxicity curves, representative of what was observed in
the clinic for these studies. Notably, the second and
third dose of AZD1480 has the same probability of tox-
icity, which is unusual, as we expect the probability of
DLT to increase with increasing dose.
In addition, four theoretical true dose-toxicity curves
were used: conservative, step-up, dose-linear and sig-
moidal, which are taken from skeletons used in our
previous study [15]. For this simulation study, the choice
of 4 theoretical dose toxicity curves from the 8 presented
in [15] were selected to ensure a range of dose toxicity
relationships were included in the analysis. The eight
true dose toxicity curves are presented in Fig. 1.
The CRM uses a Bayesian model which assumes in-
creasing probability of DLT with increasing dose [12]. It
consists of 3 components: the dose toxicity model, skel-
eton and prior distribution, which are explained in detail
in [15]. Also, the maximum acceptable toxicity level
(maximum acceptable proportion of patients experien-
cing a DLT), must be specified during the design of the
study. The skeleton is formed by specifying initial esti-
mates of probabilities of DLT at each dose. It is continu-
ally updated as new toxicity information emerges: a DLT
experienced at the current dose level would increase the
estimated probability of experiencing a DLT at the
current dose, and all higher doses; no DLT experienced
at the current dose level would reduce the estimated
probability of DLT at all dose levels. After the model is
updated, it will recommend that the next patient(s) are
Table 1 Dose-toxicity relationship for each clinical study
Study Dose DLTs Number of patients evaluable
for DLT
Proportion of patients who
experienced a DLT
P (DLT) for true dose toxicity
curve
AZD3514 250mg QD 0 6 0% 0%
500mg QD 0 6 0% 0%
1000 mg QD 1 6 17% 17%
1000 mg BID 3 6 50% 50%
2000 mg BID 4 4 100% 100%
AZD1208 120mg QD 0 3 0% 0%
240mg QD 0 3 0% 0%
480mg QD 0 3 0% 0%
700mg QD 1 4 25% 25%
900mg QD 2 3 67% 67%
AZD1480 15 mg BIDa 0 4 0% 0%
20mg BID 1 5 20% 20%
30mg BID 1 5 20% 20%
35mg BID 2 3 67% 67%
45mg BID 0 2 0% 67%
AZD4877 2mg twice
weekly
0 3 0% 0%
4mg twice
weekly
0 3 0% 0%
7mg twice
weekly
0 3 0% 0%
11mg twice
weekly
0 6 0% 0%
15mg twice
weekly
2 2 100% 100%
aTaken from another study on AZD1480
BID: twice daily; QD: once daily
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allocated the dose which is closest to but below the max-
imum acceptable toxicity level. Dose-skipping is an in-
crease from the current dose by more than 1 dose level.
We chose to not allow dose-skipping, as in clinical prac-
tice it is unlikely that this would be allowed due to an
increased safety risk. We consider six skeletons; conser-
vative, aggressive, step-up, dose-linear, sigmoidal, and
O’Quigley. The rationale for these skeletons are de-
scribed and analysed in [15], and are displayed in Fig. 2.
The maximum acceptable toxicity level of the 3 + 3
level is generally assumed to be 33% [18], but is debated
in the literature as being between 17 and 33%. Wheeler
et al [19] introduced the concept of a tipping point in
A + B designs in which they conclude that the selected
MTD in a 3 + 3 design is most likely to have a true prob-
ability ≤29.7%.
The focus of this manuscript is to evaluate the correct
determination of the MTD for each method, however it
is noted that sample size is also an important practical
consideration when conducting a clinical trial. Simula-
tion studies have shown that the CRM and 3 + 3 method
are comparable in terms of sample size needed to
Fig. 1 True dose toxicity curves individually
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determine the MTD when testing ≤5 doses [5], therefore
it is reasonable to expect similar sample sizes for the 3 +
3 and CRM method in these simulations.
Statistical analysis
The maximum acceptable toxicity level was set at 33%
to aid comparison with the 3 + 3 method. Therefore, for
each true dose-toxicity curve, the MTD was the highest
dose where the probability of DLT was below or equal
to 33%. For each true dose-toxicity curve, we simulated
1000 dose-toxicity datasets, and used the 3 + 3 method
and the extended CRM method with six different skele-
tons to identify the MTD using EAST [20]. For each
method we calculated the percentage of simulated stud-
ies where the correct MTD was identified. For the ex-
tended CRM method, if a simulation at any time during
the second stage of the method (CRM allocates next
dose) has a mean predicted posterior probability of ex-
periencing a DLT at the lowest dose that exceeds the
maximum acceptable toxicity, the simulation would stop
and not be able to find an MTD. For the 3 + 3 model, if
2 or more DLTs were experienced at the lowest dose of
a simulation the MTD could not be determined.
The extended CRM models used a single parameter
logistic model to model the dose-toxicity relationship,
with a Gaussian prior distribution for the natural loga-
rithm of the logistic model parameter of mean 0 and
variance 1.34 for each skeleton. The variance was chosen
to be 1.34 as with other published analyses [9].
For each model, we considered six skeletons; conserva-
tive, aggressive, step-up, dose-linear, sigmoidal, and
O’Quigley which are displayed in Fig. 2a. Prior to the
CRM being used to determine the next recommended
dose, the Goodman’s modification was used with cohorts
of 3 patients to match the 3 + 3 method for comparison.
After this, the CRM model was updated after each indi-
vidual patient received treatment (cohorts of 1 patient).
Dose-skipping was not allowed.
The maximum number of patients to be exposed to a
single dose level was set to be six which gives a max-
imum sample size of 30, given a maximum number of 5
cohorts. Therefore, when the model recommends a 7th
patient be assigned to a single dose level, the study will
Fig. 2 CRM skeletons and 95% prediction intervals
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end, and the MTD will be determined as the dose with
the largest estimated probability of DLT below or equal
to the maximum acceptable toxicity level (33%). No
other stopping criteria were included in the simulations.
This aids comparison with the 3 + 3 method, because an-
other dose may be explored after six patients, but no
more than 6 patients would be in a single cohort.
Results
Table 2 (section A) displays the proportion of simula-
tions where the MTD was correctly identified for each
dose-escalation method on the ‘clinical trial dose toxicity
curves’. All methods correctly identified the MTD for
AZD4877. Each CRM model correctly identified the
MTD more frequently than the 3 + 3 method for studies
AZD1208 and AZD1480. The ability of the CRM to cor-
rectly identify the MTD for AZD3514 varied consider-
ably, varying from 34.8 to 71.7%, of which the aggressive
(34.8%) and dose-linear (36.4%) skeletons were particu-
larly poor. Notably for AZD3514, only two of the six
CRM skeletons (conservative and sigmoidal) identified
the correct MTD a higher proportion of the time than
the 3 + 3 method. The percentage of simulations where
the correct MTD was identified using the conservative
and sigmoidal skeletons was fairly consistent across
studies AZD1208, AZD1480 and AZD3514, but the
other CRM skeletons varied more across studies. Specif-
ically, the percentage of simulations where the correct
MTD was identified varied between 36.4 and 98.5% for
the dose-linear skeleton, and 34.8 and 88.3% for the ag-
gressive skeleton.
Table 2 (section B) displays the proportion of simula-
tions where the MTD was correctly identified for each
method on the ‘theoretical dose toxicity curves’. Each
CRM skeleton identified the true MTD more frequently
for the conservative, step-up and dose-linear true dose
toxicity curves compared to the 3 + 3 model. However,
only the conservative CRM skeleton correctly identified
the MTD more frequently than the 3 + 3 method for the
sigmoidal dose-toxicity curve. Comparing CRM models
only, the conservative skeleton identified the correct
MTD in a higher proportion of simulations for the con-
servative, step-up and sigmoidal dose-toxicity curves,
but not the dose-linear dose-toxicity curve. Using the
CRM with initial skeleton DLT probabilities matching
the true dose toxicity curve did not always produce the
best results; for example the conservative skeleton more
frequently identified the true MTD of the sigmoidal true
dose toxicity curve than the sigmoidal skeleton.
Table 3 shows the proportion of simulations where
the MTD was correctly identified, underestimated,
overestimated or not determined, averaged over the
clinical trial dose-toxicity curves (A), theoretical dose-
toxicity curves (B), and all dose-toxicity curves (C). It is
worth noting that, on average, each method correctly
identified the MTD more frequently in the clinical trial
dose toxicity curves compared with the theoretical dose
toxicity curves. Each CRM skeleton identified the true
MTD more frequently for the clinical trial, theoretical
and all dose toxicity curves compared to the 3 + 3
method. The percentage point increase in correct iden-
tification of the MTD for the CRM skeleton compared
to the 3 + 3 method ranged from 3.3 to 12.5 for clinical
trial dose-toxicity curves, 2.4 to 18.1 for theoretical
dose-toxicity curves and 3.9 to 13.9 for all dose-toxicity
curves. Compared to the 3 + 3 method, each CRM skel-
eton was more than twice as likely to overestimate the
MTD and less than half as likely to underestimate the
MTD. The MTD could be determined in over 99% of
simulations for clinical trial dose-toxicity curves using
each method, but could not be determined for the the-
oretical dose-toxicity curves for approximately 5% of
simulations using the CRM skeleton and 15% of 3 + 3
simulations.
The aggressive skeleton was the skeleton with the low-
est mean proportion of simulations identifying the true
MTD for the clinical trial dose-toxicity curves (68.5%),
the other CRM methods had similar proportions to each
other (73.8 to 76.7%). For the theoretical dose-toxicity
curves, there was more variation between the CRM skel-
etons in the mean proportion of simulations where the
true MTD was identified. The highest percentage was
for the conservative skeleton (52.9%), followed by the
sigmoidal skeleton (46.4%). Similarly, for all dose-
toxicity curves, there was some variation in the average
percentage of simulations where the true MTD was se-
lected, and the highest frequency was by the conserva-
tive and sigmoidal skeletons. The conservative skeleton
was the skeleton in the CRM method which overesti-
mated the MTD least frequently. The dose-linear and
aggressive skeletons overestimated the MTD consider-
ably more frequently than other skeletons, however they
also underestimated the MTD somewhat less frequently
than other skeletons.
Discussion
This analysis compared the extended CRM, using
various skeletons, with the 3 + 3 method for clinical and
theoretical ‘true’ dose-toxicity scenarios. The results pro-
vide further support that the CRM is more likely to
identify the true MTD compared to the 3 + 3 method. It
is notable that the CRM less frequently underestimated
and more frequently overestimated the MTD compared
to the 3 + 3 method, providing evidence the 3 + 3
method is more conservative. This overestimation can
be mitigated by adapting the CRM method [21]. The
choice of skeleton has significant impact on the likeli-
hood of overestimating or underestimating the MTD,
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and this should be taken into consideration when plan-
ning dose-escalation trials using this method and high-
lights the importance of simulating the operating
characteristics for the dose escalation during the design
stage.
To our knowledge this is the first study to compare
skeletons for the CRM method in a variety of dose-
toxicity relationships. It builds on our previous analysis,
where the CRM method with various skeletons was ap-
plied retrospectively to clinical trial data from AZD3514
study 1, which found that the CRM method required
fewer patients to identify the true MTD and allocated
fewer patients to sub-optimal and toxic doses [15]. The
majority of studies implementing the CRM method uses
the skeleton from O’Quigley et al [22] without providing
justification [9]. In our literature review we found the
majority of dose-escalation studies did not provide the
skeletons or explain how they were obtained.
When taking into account all of the simulations, the
CRM estimated the true MTD more frequently than the
3 + 3 method. The CRM overestimated the true MTD
more frequently than the 3 + 3 method. One probable
reason for this difference is that the 3 + 3 method actu-
ally has maximum acceptable toxicity of between 17% (1
out of 6 patients) and 33% (2 out of 6 patients). The
choice of skeleton can be used to reduce the chances of
overestimation of the MTD and further lowered by
reducing the prior probabilities in each the skeleton, al-
though this may cause slower dose-escalation requiring
more patients to identify the MTD and exposing more
patients to a potentially toxic drug or a sub-optimal
dose. James et al describes how clinical opinion should
also be used in conjunction with the CRM recommenda-
tion for determining the next dose [15], which improves
the flexibility of dose choice and could also prevent the
MTD being overestimated.
The CRM and 3 + 3 method identified the true MTD
more frequently in the clinical trial dose toxicity curves
compared to the theoretical dose-toxicity curves. One
likely reason for this is the dose toxicity curves from the
clinical trials curves are steeper and often the dose im-
mediately greater than the MTD has a considerably
greater probability of toxicity. For instance, the dose im-
mediately above the MTD has probability of toxicity of
50% or greater for all the clinical trial dose-toxicity
curves, whereas two of the four theoretical dose-toxicity
curves have this probability at less than 50%.
There was little difference between the skeletons in
the average percentage of MTDs correctly identified for
the clinical trial dose-toxicity curves. However, there
were considerable differences between skeletons in the
average percentage of MTDs correctly identified for the
theoretical dose-toxicity curves. Conservative and
sigmoidal skeletons correctly identified the MTD in
Table 2 Proportion of simulations where true MTD identified
A. Clinical trial dose toxicity curves
Dose escalation method True dose toxicity curve
AZD3514 AZD1208 AZD1480 AZD4877
3 + 3 64.9 50.5 45.5 100.0
Extended CRM Conservative 71.7 66.8 60.9 100.0
Aggressive 34.8 88.3 51.0 100.0
Step-up 57.6 88.9 60.1 100.0
Dose-Linear 36.4 98.5 60.4 100.0
Sigmoidal 71.4 66.8 68.4 100.0
O’Quigley 56.5 78.2 59.8 100.0
B. Theoretical dose toxicity curves
Dose escalation method True dose toxicity curve
Conservative Step-up Dose-linear Sigmoidal
3 + 3 33.1 22.7 36.8 46.6
Extended CRM Conservative 63.4 43.9 53.9 50.3
Aggressive 44.6 30.8 48.2 33.9
Step-up 44.5 29.8 64.2 32.6
Dose-Linear 39.7 23.6 62.7 22.8
Sigmoidal 51.7 33.0 67.8 33.2
O’Quigley 40.4 27.3 65.9 28.9
The method which correctly identified the MTD of a true dose toxicity curve in the greatest percentage of simulations is italicised and emboldened. The method
which correctly identified the MTD of a true dose toxicity curve in the lowest percentage of simulations is italicised and underlined
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approximately half of the simulations, aggressive and
dose-linear least frequently identified the MTD correctly
identified in just under 40% of simulations. Looking
closer at the aggressive and dose-linear skeletons, their
ability to identify the true MTD varies more between
dose-toxicity curves compared to the other skeletons.
They were particularly poor at identifying the true MTD
in AZD3514 with correct identification in just over a
third of simulations, which was considerably less than
the other skeletons and the 3 + 3 design. However, the
dose-linear skeleton identified the correct MTD in study
AZD1208 more frequently than any other skeleton. The
conservative method was the least variable skeleton in
terms of percentage of correct MTD identification. Not-
ably all methods identified the true MTD of the theoret-
ical Sigmoidal dose-toxicity-curve in 50% of fewer
simulations, on closer inspection this is likely due to the
dose above the true MTD having a 35% probability of
DLT, which is just above the 33% maximum acceptable
toxicity level.
The choice of skeleton had considerable influence on
the frequency of simulations underestimating or over-
estimating the MTD. The conservative and sigmoidal
skeletons had the lowest frequency of overestimations,
and the highest frequency of underestimations, suggest-
ing these may be the most conservative methods. The
dose-linear and aggressive skeletons had the highest
frequency of overestimations and lowest frequency of
underestimations, suggesting these may be the least con-
servative methods.
Notably starting with a skeleton which matched the
true dose-toxicity curve did not guarantee it was the
Table 3 Summary statistics about each dose escalation method
A. Clinical trials dose toxicity curves
Dose escalation method MTD selected by dose-escalation method (%)
True selected Underestimated Overestimated < lowest dose
3 + 3 65.2 31.8 2.3 0.7
Extended CRM Step-up 76.7 9.0 13.9 0.4
Dose-Linear 76.7 4.2 21.5 0.4
O’Quigley 76.6 11.6 14.4 0.4
Conservative 74.8 16.6 8.2 0.4
Sigmoidal 73.8 14.7 8.3 0.4
Aggressive 68.5 6.7 24.4 0.4
B. Theoretical dose toxicity curves
Dose escalation method MTD selected by dose-escalation method (%)
True selected Underestimated Overestimated < lowest dose
3 + 3 34.8 42.6 7.3 15.3
Extended CRM Conservative 52.9 21.6 20.7 4.9
Sigmoidal 46.4 19.1 29.9 4.6
Step-up 42.8 22.1 30.1 5.1
O’Quigley 40.6 21.4 32.9 5.1
Aggressive 39.4 21.3 34.5 4.9
Dose-Linear 37.2 18.3 40.4 4.1
C. All dose toxicity curves
Dose escalation method MTD selected by dose-escalation method (%)
True selected Underestimated Overestimated < lowest dose
3 + 3 50.0 37.2 4.8 8.0
Extended CRM Conservative 63.9 19.1 14.4 2.6
Sigmoidal 61.5 16.9 19.1 2.5
Step-up 59.7 15.5 22.0 2.8
O’Quigley 57.1 16.5 23.6 2.7
Dose-Linear 55.5 11.3 31.0 2.2
Aggressive 53.9 14.0 29.4 2.6
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skeleton most likely to identify the MTD. For instance,
the conservative skeleton identified the true MTD of the
step-up dose-toxicity curve more frequently than the
step-up skeleton. This suggests that it may be less im-
portant to accurately specify a skeleton that matches the
true dose toxicity relationship during the design of a
study however to understand the characteristics of a
chosen skeleton, simulation is advised. One alternative
approach which should be considered is conducting the
CRM on multiple skeletons simultaneously and taking a
Bayesian model averaging (BMA) approach as proposed
by Yin Y & Yuan Y [13], where a recommendation for
how to apply skeletons can be described by Haitao P &
Yuan Y [23].
Strengths limitations
This study has several strengths. It uses dose-toxicity
curves from four compounds from phase 1 clinical trials
where patients were allocated one of 5 or more doses,
and information on patient characteristics were available.
It also uses four theoretical dose-toxicity curves which
were derived from physician’s beliefs about possible rela-
tionships between dose and toxicity. EAST, advanced
statistical software was utilised to conduct simulation
studies to assess the ability of the CRM, with various
skeletons and the 3 + 3 method to identify the true MTD
for these dose-toxicity curves. A limitation of this study
is that we could not incorporate clinical opinion as part
of the simulations. Dose levels do not all have the same
multiplicative increments and intermediate dose levels
may not have been specified apriori but this analysis uti-
lised real world data so was based on those retrospective
dose levels.
Implications
This research has implications for planning and con-
ducting future phase I oncology dose escalation trials.
Simulations support the existing literature that the CRM
more often correctly identifies the true MTD compared
to the 3 + 3 design. The importance of selecting an ap-
propriate skeleton and understanding its characteristics
for different underlying truths has been shown, and
should support the study objectives. Several skeletons
have been proposed, and compared using a variety of
true dose toxicity relationships, and suggestions have
been made for their use in future trials.
Conclusions
Generally, the CRM method more frequently identifies
the true MTD compared to the 3 + 3 method, even when
the optimal dose-toxicity curve is unknown. Choice of
the skeleton should depend on study objectives. This
manuscript describes skeletons that may be used where
there is limited data available to describe dose-toxicity
relationship and raises the importance of further explor-
ation into this. We advise investigators who are using
CRM methods to make available their initial priors and
final dose-toxicity graphs so optimal generic graphs can
be derived and to support the uptake of these methods.
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